Hummingbird Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- Hummingbird Bioscience's estimated annual revenue is currently $20M per year.
- Hummingbird Bioscience's estimated revenue per employee is $155,000
- Hummingbird Bioscience's total funding is $150M.
Employee Data
- Hummingbird Bioscience has 129 Employees.
- Hummingbird Bioscience grew their employee count by -16% last year.
Hummingbird Bioscience Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.9M | 63 | -24% | $15M | N/A |
#2 | $20M | 129 | -16% | $150M | N/A |
#3 | $3.7M | 48 | -6% | $53M | N/A |
#4 | $5.4M | 35 | -8% | N/A | N/A |
#5 | $3.6M | 23 | -18% | N/A | N/A |
#6 | $3.4M | 22 | 0% | N/A | N/A |
#7 | $5.4M | 35 | 6% | N/A | N/A |
#8 | $7.1M | 46 | -26% | N/A | N/A |
#9 | $36.1M | 233 | 4% | N/A | N/A |
#10 | $3.1M | 20 | -61% | N/A | N/A |
What Is Hummingbird Bioscience?
Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing revolutionary therapies against hard-to-drug targets for improved treatment outcomes. We harness the latest advances in systems biology and data science to better understand and solve the underlying causes of disease and guide development of our therapeutics. Enabled by our proprietary Rational Antibody Discovery platform, we discover antibodies against optimal yet elusive epitopes on important targets that have not been successfully drugged, unlocking novel mechanisms of action. We are advancing a rich pipeline of first- and best-in-class drug candidates in oncology, autoimmune and infectious diseases, in collaboration with global partners in academia and industry. Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development. Together we aim to accelerate the journey of new drugs from concept to clinical care. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird on LinkedIn and Twitter (@hummingbirdbio).
keywords:N/A
$150M
Total Funding
129
Number of Employees
$20M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Hummingbird Bioscience's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Chief Technology Officer | Reveal Email/Phone |
3 | Senior Clinical Data Manager | Reveal Email/Phone |
4 | Head Regulatory Science | Reveal Email/Phone |
5 | VP Program Development | Reveal Email/Phone |
6 | Senior Research Scientist | Reveal Email/Phone |
7 | Director, CEO and Co-Founder | Reveal Email/Phone |
8 | CSO, Co-Founder | Reveal Email/Phone |
9 | Senior Research Associate | Reveal Email/Phone |
10 | Senior Director, Global Head Quality Assurance | Reveal Email/Phone |
Hummingbird Bioscience News
Hummingbird Bioscience is a clinical-stage biotechnology company with a proprietary Rational Antibody Discovery (RAD) platform, developing a...
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a P ...
HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved t ...
HOUSTON and SINGAPORE, July 12, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, and The University of Texas MD Anderson Cancer C ...
Other Companies in Singapore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.1M | 129 | N/A | N/A |
#2 | $16.8M | 129 | -23% | N/A |
#3 | $46.2M | 131 | -2% | N/A |
#4 | $7.5M | 132 | 8% | N/A |
#5 | $33.1M | 132 | 8% | N/A |